Preclinical assessment of a new live ...
Document type :
Compte-rendu et recension critique d'ouvrage
PMID :
Title :
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis
Author(s) :
Levillain, Florence [Auteur]
Institut de pharmacologie et de biologie structurale [IPBS]
Kim, Hongmin [Auteur]
Yonsei University
Woong Kwon, Kee [Auteur]
Yonsei University
Clark, Simon [Auteur]
Public Health England [Salisbury] [PHE]
Cia, Felipe [Auteur]
London School of Hygiene and Tropical Medicine [LSHTM]
Malaga, Wladimir [Auteur]
Yonsei University
Lanni, Faye [Auteur]
Public Health England [Salisbury] [PHE]
Brodin, Priscille [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Gicquel, Brigitte [Auteur]
Génétique mycobactérienne - Mycobacterial genetics
Shenzhen Univerisity [Shenzhen]
Guilhot, Christophe [Auteur]
Yonsei University
Bancroft, Gregory [Auteur]
London School of Hygiene and Tropical Medicine [LSHTM]
Williams, Ann [Auteur]
Public Health England [Salisbury] [PHE]
Jae Shin, Sung [Auteur]
Yonsei University
Poquet, Yannick [Auteur]
Institut de pharmacologie et de biologie structurale [IPBS]
Neyrolles, Olivier [Auteur correspondant]
Institut de pharmacologie et de biologie structurale [IPBS]
Institut de pharmacologie et de biologie structurale [IPBS]
Kim, Hongmin [Auteur]
Yonsei University
Woong Kwon, Kee [Auteur]
Yonsei University
Clark, Simon [Auteur]
Public Health England [Salisbury] [PHE]
Cia, Felipe [Auteur]
London School of Hygiene and Tropical Medicine [LSHTM]
Malaga, Wladimir [Auteur]
Yonsei University
Lanni, Faye [Auteur]
Public Health England [Salisbury] [PHE]
Brodin, Priscille [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Gicquel, Brigitte [Auteur]
Génétique mycobactérienne - Mycobacterial genetics
Shenzhen Univerisity [Shenzhen]
Guilhot, Christophe [Auteur]
Yonsei University
Bancroft, Gregory [Auteur]
London School of Hygiene and Tropical Medicine [LSHTM]
Williams, Ann [Auteur]
Public Health England [Salisbury] [PHE]
Jae Shin, Sung [Auteur]
Yonsei University
Poquet, Yannick [Auteur]
Institut de pharmacologie et de biologie structurale [IPBS]
Neyrolles, Olivier [Auteur correspondant]
Institut de pharmacologie et de biologie structurale [IPBS]
Journal title :
Vaccine
Pages :
1416-1423
Publisher :
Elsevier
Publication date :
2020-02
ISSN :
0264-410X
English keyword(s) :
Tuberculosis
Mycobacterium tuberculosis
BCG
Vaccine
Mycobacterium tuberculosis
BCG
Vaccine
HAL domain(s) :
Sciences du Vivant [q-bio]/Immunologie/Vaccinologie
English abstract : [en]
Tuberculosis still claims more lives than any other pathogen, and a vaccine better than BCG is urgently needed. One of the challenges for novel TB vaccines is to protect against all Mycobacterium tuberculosis lineages, ...
Show more >Tuberculosis still claims more lives than any other pathogen, and a vaccine better than BCG is urgently needed. One of the challenges for novel TB vaccines is to protect against all Mycobacterium tuberculosis lineages, including the most virulent ones, such as the Beijing lineage. Here we developed a live attenuated M. tuberculosis mutant derived from GC1237, a Beijing strain responsible for tuberculosis outbreaks in the Canary Islands. The mutant strain is inactivated both in the Rv1503c gene, responsible for surface glycolipid synthesis, and in the two-component global regulator PhoPR. This double mutant is as safe as BCG in immunodeficient SCID mice. In immune-competent mice and guinea pigs, the mutant is as protective as BCG against M. tuberculosis strains of common lineage 4 (Euro-American). By contrast, in mice the vaccine is protective against a M. tuberculosis strain of lineage 2 (East-Asian, Beijing), while BCG is not. These results highlight differences in protection efficacy of live attenuated M. tuberculosis-derived vaccine candidates depending on their genetic background, and provide insights for the development of novel live vaccines against TB, especially in East-Asian countries where M. tuberculosis strains of the Beijing family are highly dominant.Show less >
Show more >Tuberculosis still claims more lives than any other pathogen, and a vaccine better than BCG is urgently needed. One of the challenges for novel TB vaccines is to protect against all Mycobacterium tuberculosis lineages, including the most virulent ones, such as the Beijing lineage. Here we developed a live attenuated M. tuberculosis mutant derived from GC1237, a Beijing strain responsible for tuberculosis outbreaks in the Canary Islands. The mutant strain is inactivated both in the Rv1503c gene, responsible for surface glycolipid synthesis, and in the two-component global regulator PhoPR. This double mutant is as safe as BCG in immunodeficient SCID mice. In immune-competent mice and guinea pigs, the mutant is as protective as BCG against M. tuberculosis strains of common lineage 4 (Euro-American). By contrast, in mice the vaccine is protective against a M. tuberculosis strain of lineage 2 (East-Asian, Beijing), while BCG is not. These results highlight differences in protection efficacy of live attenuated M. tuberculosis-derived vaccine candidates depending on their genetic background, and provide insights for the development of novel live vaccines against TB, especially in East-Asian countries where M. tuberculosis strains of the Beijing family are highly dominant.Show less >
Language :
Anglais
Popular science :
Non
Source :
Files
- document
- Open access
- Access the document
- Levillaina-etal-2020_A_live_attenuated_vaccine_confers.pdf
- Open access
- Access the document
- Levillaina-etal-2020_A_live_attenuated_vaccine_confers.pdf
- Open access
- Access the document